Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketorolac 30 mg vs 20 mg for Acute Pain in the Emergency Department
NCT07816302Phase 3Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2026
- Primary completion
- Mar 2027
01
Overview
Phase 3, randomised, double-blind trial of ketorolac in pain (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Pain score at 30 minutes. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketorolac
03
Conditions
pain
Beyond the preview
Go deeper on NCT07816302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816302.